At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SGMT Sagimet Biosciences Inc.
Pre-Market Trading 11-05 06:30:30 EST
5.42
+0.09
+1.69%
High5.67
Low5.18
Vol1.42M
Open5.31
D1 Closing5.33
Amplitude9.19%
Mkt Cap172.97M
Tradable Cap87.79M
Total Shares31.91M
T/O7.69M
T/O Rate8.76%
Tradable Shares16.20M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
BRIEF-Sagimet Biosciences Announces Successful Completion Of End-Of-Phase 2 Interactions With FDA On The Development Of Denifanstat For Mash Phase 3 Program Initiation Expected By End Of 2024
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Announces Publication of Results From Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Mash in the Lancet Gastroenterology & Hepatology
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.